Attached files
| file | filename |
|---|---|
| EX-31.1 - EXXHIBIT 31.1 - Cyclacel Pharmaceuticals, Inc. | t1600767_ex31-1.htm |
| EX-31.2 - EXHIBIT 31.2 - Cyclacel Pharmaceuticals, Inc. | t1600767_ex31-2.htm |
| EX-32.1 - EXHIBIT 32.1 - Cyclacel Pharmaceuticals, Inc. | t1600767_ex32-1.htm |
| EX-32.2 - EXHIBIT 32.2 - Cyclacel Pharmaceuticals, Inc. | t1600767_ex32-2.htm |
| 10-K - FORM 10-K - Cyclacel Pharmaceuticals, Inc. | t1600767-10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statements (Nos. 333-205153, 333-183483, and 333-143786) on Form S-8 and (No. 333-187801) on Form S-3 of Cyclacel Pharmaceuticals, Inc. of our report dated March 29, 2016, relating to our audit of the consolidated financial statements, which appear in this Annual Report on Form 10-K of Cyclacel Pharmaceuticals, Inc. for the year ended December 31, 2015. On October 26, 2015, we changed the name of our firm from McGladrey LLP to RSM US LLP.
/s/ RSM US LLP
New York, New York
March 29, 2016
March 29, 2016